Trivalent Influenza Vaccine (Split Virion)

Influenza vaccine (split virion), inactivated apply the most advanced technology in the world to production of influenza vaccine and arrange vaccine production and quality control according to current influenza virus recommended by who. Each quality index of the influenza vaccine is excellent. [eligibles] susceptible individuals and persons liable to be afflicted with the associated complications, such as children, elderly persons and individuals in the epidemic area. [function and use] the product can induce immunity against influenza virus in recipients following immunization. It is used to prevent the infections of the prevalent strains of influenza viruses. [specifications] 0.25 ml or 0.5 ml per container. 0.25 ml per single human dose (used for children aged between 6 months and 3 years) .shall contain 7.5μg of influenza haemagglutinin of each influenza virus strain. 0.5 ml per single human dose (used for adult and children aged above 3 years) shall contain 15μg of influenza haemagglutinin of each influenza virus strain. [advantages] (1) apply centrifugal purification and column chromatography purification technology to purifying virus and obtained the patent certificate of making use of sepharose4ff column chromatography technology for vaccine manufacture. The product quality index is excellent and the purity is high; (2) high-level gmt of conversion rate of serum antibody with safety and reliable effect for prevention